Call / Whatsapp
+918447748545

Published on: Apr 04, 2020
2 minute read
By: Dr Rajan Choudhary

THE CHALLENGES FACED IN MAKING A VACCINE FOR COVID-19 — Part 2

Previously we’ve seen the difficulties researches face in trying to make a vaccine. But even if we make a vaccine, that’s just half the battle. Viruses are unique because they can mutate, and they can mutate to astonishing degrees. In humans mutations to tiny parts of our DNA can cause severe diseases or even death. In viruses mutations can change their structure, making them more infective and giving them a new coat. It gives them a survival advantage, the ability to evade our immune system and make our vaccines ineffective. This is why we need a new flu vaccine every year.

If it takes months to a year to develop a vaccine, it will be based off the virus found in December 2019. By this time the virus may have spread and mutated to such a degree that it is not effective. This does not mean all the effort was for nothing. Going through the steps and understanding the issues faced with making a COVID-19 vaccine can make the process quicker for subsequent vaccines against its mutated versions.

https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away So Long to Develop a Vaccine

FAILURES FROM THE PAST

These issues were faced during the Ebola and Zika virus epidemics, and many large companies are understandably hesitant to develop vaccines for COVID-19. Ebola first broke out in 2014, and it was only in December 2019 that the first vaccine was approved for use by the European Commission and the United States. This is despite multiple large institutes in Canada and the UK working together to develop it.

13 different Ebola vaccine candidates had been identified soon after the outbreak, but none had been tested on humans. Unfortunately this is the most expensive part of development, and the area biopharmecuticals stand to loose the most money. Return on investments is also low, since epidemics usually take place in poorer countries, and the potential customers are unable to pay the high prices for these brand new treatments. It is an unfortunate realisation that research into medicines is driven by rich countries, for diseases that affect the rich.

https://newint.org/features/web-exclusive/2016/06/16/why-did-the-market-fail-to-produce-an-ebola-vaccine Ebola

WHERE ARE WE NOW?

This is all well and good, but what does it mean for COVID-19? We know we cannot rush a vaccine, because a poorly designed vaccine with unknown side effects can cause more harm than good, especially if given to children or the elderly. Currently the WHO are tracking 31 different attempts at making a COVID-19 vaccine, using different methods as discussed before. All of these are currently in the pre-clinical stage, focusing on isolating parts of the virus and creating a target the body will recognise and react to.

Researchers at the University of Queensland were one of the first to start using the genetic code of COVID-19, released openly by Chinese researchers. They have developed a test vaccine within 6 weeks using state-of-the-art genetic techniques, used for the first time. If animal models prove successful then human testing might begin within 6 months. In the pharmaceutical industry advancements this quick are almost unheard of.

Additionally over 293 clinical trials are taking place in China using existing drugs on the market. The advantage is we already know these drugs are safe to use in humans, but we are trying to work out if they will work against COVID-19. Some scientists are also looking at medications that were initially developed against SARS and MERS, but never completed because these outbreaks died down and the medication was no longer required.

https://www.aljazeera.com/news/2020/03/china-recovered-develop-effective-covid-19-treatments-200302082850237.html COVID-19 treatments

https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1 WHO news

https://www.theverge.com/2020/2/28/21156385/covid-coronavirus-vaccine-treatment-moderna-remdesivir-research COVID-19 treatment

Its not all doom and gloom. Challenges drive innovation, and we are already benefitting from this. New forms of genetic sequencing, new methods for extracting viral proteins, new techniques in creating a vaccine. These innovations are already benefitting us on the drive to create an effective vaccine for COVID-19, and they will benefit us in the future when the next pandemic hits.

Dr Rajan Choudhary, Product Manager Second Medic UK

www.secondmedic.com

Read Blog

Human Metapneumovirus (HMPV): Treatment & Symptoms

Human Metapneumovirus (HMPV) is a respiratory virus that causes illness in people of all ages, particularly young children, older adults, and people with weakened immune systems. The virus can lead to conditions such as bronchitis, pneumonia, and upper respiratory infections. With rising cases globally and in India, awareness about HMPV, its symptoms, and available treatment options is essential.

In this blog, we'll break down everything you need to know about Human Metapneumovirus (HMPV): Treatment & Symptoms in easy-to-understand language.

What is Human Metapneumovirus (HMPV)?

HMPV is a virus that belongs to the Paramyxoviridae family—the same group of viruses responsible for illnesses like RSV (Respiratory Syncytial Virus) and mumps. It was first discovered in 2001 but is now known to have been circulating for decades.

The virus mainly affects the respiratory tract and can range from mild cold-like symptoms to severe lower respiratory infections. It spreads most commonly in late winter and spring, similar to flu season.

HMPV in India: Current Overview

In 2025, several hospitals in India have seen a rise in cases of HMPV among children and elderly patients. Though not as widely known as COVID-19 or flu, Human Metapneumovirus is a common cause of pediatric hospital admissions during respiratory infection surges.

Doctors advise taking it seriously because it can mimic flu or pneumonia, making early diagnosis crucial.

Common Symptoms of HMPV

The symptoms of HMPV are similar to other respiratory viruses. They can range from mild cold-like symptoms to severe breathing difficulties, especially in vulnerable groups.

Main Symptoms Include:

Fever
Cough
Runny nose
Nasal congestion
Sore throat
Wheezing
Shortness of breath
Fatigue
Loss of appetite (especially in children)

In severe cases, it can lead to bronchitis or pneumonia.

How is HMPV Transmitted?

Human Metapneumovirus spreads from person to person through:

Coughing and sneezing
Close personal contact
Touching contaminated surfaces or hands

The virus can survive on surfaces like toys, doorknobs, and tables for several hours. That’s why regular handwashing and hygiene are essential.

How is HMPV Diagnosed?

Since HMPV symptoms resemble other viral infections, a lab test is the only way to confirm the virus.

Tests may include:

RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) for detecting viral RNA
Nasopharyngeal swabs
Rapid antigen tests (less common)

In India, you can book respiratory virus panels or flu-like illness tests from diagnostic labs like Thyrocare through SecondMedic to check for multiple viruses including HMPV.

Human Metapneumovirus (HMPV): Treatment

There is no specific antiviral drug for HMPV. Treatment is mainly supportive, aimed at relieving symptoms.

Supportive Treatments:

Fever reducers like paracetamol
Cough suppressants
Steam inhalation
Hydration (drinking fluids)
Rest

Hospitalization is required if:

Breathing becomes difficult
Oxygen levels drop
Patient is elderly, a young child, or has chronic illnesses (like asthma or heart disease)

Doctors may provide oxygen therapy or nebulizers to ease breathing in severe cases.

How to Prevent HMPV

As with many respiratory infections, prevention is the best protection.

Tips to Avoid Infection:

Wash your hands regularly with soap and water.
Use alcohol-based hand sanitizers when outside.
Cover mouth and nose when sneezing or coughing.
Avoid touching your face, especially eyes and nose.
Disinfect commonly used surfaces at home and work.
Avoid close contact with sick individuals.
Wear a mask in crowded places during flu season.

There is no vaccine for HMPV yet, but researchers are working on developing one.

Who is Most at Risk?

Infants and toddlers (under 5 years)
Adults over 65
People with weakened immune systems
Individuals with chronic respiratory or heart diseases

These groups may experience more severe symptoms and need urgent care if infected.

When to See a Doctor

You should consult a doctor if:

Symptoms last more than 5–7 days
Breathing becomes difficult
Fever is very high or persistent
There's chest pain or confusion
A child has a bluish face or lips

Early intervention can prevent complications.

Recommended Tests on SecondMedic (Powered by Thyrocare)

While there is no HMPV-specific test for home collection, you can book tests like:

Complete Blood Count (CBC)
CRP (C-Reactive Protein)
Respiratory Pathogen Panel
Influenza A & B Detection
RT-PCR Viral Panels (on request)

Visit SecondMedic’s Lab Test Section to explore packages and book your test online.

Conclusion

Human Metapneumovirus (HMPV) is a growing cause of respiratory illness in India, especially in children and the elderly. Though there is no specific cure, early diagnosis and symptom-based treatment can help patients recover fully. Practicing good hygiene and avoiding close contact with sick people are the best ways to prevent infection.

Stay informed and protect your loved ones. For detailed insights and medical advice, bookmark this guide on "Human Metapneumovirus (HMPV): Treatment & Symptoms."

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.